Contineum Therapeutics' PIPE-307 Shows Potential for Treating RRMS, Moves to Phase 2

PIPE-307, a potentially first-in-class M1 receptor antagonist under development for patients with relapse-remitting multiple sclerosis (RRMS), has published encouraging preclinical data. Contineum Therapeutics is a biopharmaceutical company focused on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications. The released information offers preliminary proof that PIPE-307 selectively inhibits the muscarinic type 1 M1 receptor. For the treatment of RRMS, Contineum Therapeutics thinks that PIPE-307 offers a unique and scientifically proven strategy.

The most prevalent kind of MS, known as RRMS, affects the brain and spinal cord and causes demyelinating lesions. Loss of myelin in demyelinating illnesses causes axons to transmit signals more slowly, which ultimately results in a permanent loss of neuronal function. According to Contineum Therapeutics, RRMS's immune-mediated actions stimulate M1 signalling by raising acetylcholine concentrations locally, which in turn suppresses OPC development and remyelination. PIPE-307 has the ability to promote OPC maturation and axon remyelination by inhibiting M1 and releasing this inhibitory brake on development.

Contineum has started a Phase 2 multi-center randomised double-blind placebo-controlled proof-of-concept clinical trial in RRMS patients (NCT06083753) and has finished two Phase 1 clinical studies of PIPE-307 in healthy volunteers. A number of clinical and imaging endpoints that are sensitive to alterations in remyelination in RRMS patients will be measured as part of the VISTA study, which will evaluate safety and effectiveness in individuals with RRMS. A worldwide license and development agreement with Janssen Pharmaceutica NV, one of Johnson & Johnson's Janssen Pharmaceutical Companies, provides the basis for the development of PIPE-307.